BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10861572)

  • 21. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
    Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
    Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.
    Dressman MA; Baras A; Malinowski R; Alvis LB; Kwon I; Walz TM; Polymeropoulos MH
    Cancer Res; 2003 May; 63(9):2194-9. PubMed ID: 12727839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer.
    Ohta JI; Miyoshi Y; Uemura H; Fujinami K; Mikata K; Hosaka M; Tokita Y; Kubota Y
    Clin Cancer Res; 2001 Aug; 7(8):2463-7. PubMed ID: 11489827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization.
    Young SR; Liu WH; Brock JA; Smith ST
    Genes Chromosomes Cancer; 1996 Jun; 16(2):130-7. PubMed ID: 8818660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Relationship between aneuploidy of chromosome 17 and amplification of HER-2/neu gene in the different histological type of breast cancer].
    Kuroso K; Ueda Y; Mori Y
    Rinsho Byori; 2004 Nov; 52(11):897-9. PubMed ID: 15658468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
    Bartlett JM; Campbell FM; Mallon EA
    Am J Clin Pathol; 2008 Dec; 130(6):920-6. PubMed ID: 19019769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
    Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
    J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic and pathologic significance of 1p, 17p, and 18q aneusomy and the ERBB2 gene in colorectal cancer and related normal colonic mucosa.
    Cianciulli A; Cosimelli M; Marzano R; Merola R; Piperno G; Sperduti I; de la Iglesia F; Leonardo G; Graziano F; Mancini R; Guadagni F
    Cancer Genet Cytogenet; 2004 May; 151(1):52-9. PubMed ID: 15120910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
    Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
    Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous imaging of membrane antigen and the corresponding chromosomal locus in pathology archives.
    Igarashi H; Yamashita K; Suzuki M; Kitayama Y; Isogaki J; Maruyama K; Sunayama K; Tsuda H; Ozawa T; Kiyose S; Sugimura H
    Pathol Int; 2005 Dec; 55(12):753-6. PubMed ID: 16287489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers: three-dimensional analysis of intranuclear localization of centromere 17 and HER-2 signals.
    Itoh H; Miyajima Y; Umemura S; Osamura RY
    Cancer; 2008 Apr; 114(2):134-40. PubMed ID: 18306351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer.
    Rennstam K; Baldetorp B; Kytölä S; Tanner M; Isola J
    Cancer Res; 2001 Feb; 61(3):1214-9. PubMed ID: 11221853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
    Mrhalová M; Kodet R; Strnad P
    Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes.
    Kao J; Pollack JR
    Genes Chromosomes Cancer; 2006 Aug; 45(8):761-9. PubMed ID: 16708353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of chromosomal aneusomy by fluorescence in situ hybridization in fine-needle aspirates from breast tumors: application to the preoperative diagnosis of breast carcinoma.
    Tsukamoto F; Miyoshi Y; Koyama H; Watatani M; Sasa M; Shiba E; Takami S; Inazawa J; Noguchi S
    Cancer; 2000 Dec; 90(6):373-8. PubMed ID: 11156521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of heterozygosity and allelic imbalance in apocrine adenosis of the breast.
    Selim AG; Ryan A; El-Ayat GA; Wells CA
    Cancer Detect Prev; 2001; 25(3):262-7. PubMed ID: 11425268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.